nymox.png
NYMOX Appeals Deficiency Letter
January 06, 2023 16:30 ET | Nymox Pharmaceutical Corporation
IRVINE, Calif., Jan. 06, 2023 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the “Company”) reports that on January 4, 2023 the Company received a deficiency letter from The...
nymox.png
NYMOX Announces New Marketing Submission for NYMOZARFEX™ for BPH
December 05, 2022 09:30 ET | Nymox Pharmaceutical Corporation
IRVINE, Calif., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the “Company”) is pleased to announce today that a new formal submission has been made by the...
nymox.png
May 2023 Market Cap Requirement Update
November 25, 2022 15:10 ET | Nymox Pharmaceutical Corporation
IRVINE, Calif., Nov. 25, 2022 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the “Company”) reports that on November 18, 2022 the Company received a deficiency letter from...
nymox.png
NYMOX Provides Current Update
September 13, 2022 09:30 ET | Nymox Pharmaceutical Corporation
IRVINE, Calif., Sept. 13, 2022 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to provide a current update on business developments. The Company has corresponded with...
nymox.png
NYMOX Updates Shareholders
July 15, 2022 09:30 ET | Nymox Pharmaceutical Corporation
IRVINE, Calif., July 15, 2022 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) today announced an update to its shareholders regarding progress in the Company business activities....
nymox.png
NYMOX Receives Deficiency Letter from NASDAQ
July 14, 2022 12:18 ET | Nymox Pharmaceutical Corporation
IRVINE, Calif., July 14, 2022 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) reports that on July 7, 2022 the Company received a deficiency letter from NASDAQ stating that the...
nymox.png
NYMOX Receives RTF letter from FDA
May 23, 2022 08:30 ET | Nymox Pharmaceutical Corporation
IRVINE, Calif., May 23, 2022 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) reports today that it has received a Refusal to File (“RTF”) letter from FDA on Friday May 20th at...
nymox.png
Nymox Announces Closing of $6.4 Million Financing
April 04, 2022 09:45 ET | Nymox Pharmaceutical Corporation
IRVINE, Calif., April 04, 2022 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the “Company”) is pleased to announce that it has closed its $6.4 million financing announced in...
nymox.png
Nymox Announces $5 Million Registered Direct Offering
March 18, 2022 08:30 ET | Nymox Pharmaceutical Corporation
IRVINE, Calif., March 18, 2022 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) today announced it has entered into definitive agreements with institutional and accredited...
nymox.png
NYMOX Announces Submission of New Drug Application (NDA) to the FDA for Fexapotide Triflutate
March 03, 2022 11:00 ET | Nymox Pharmaceutical Corporation
IRVINE, Calif., March 03, 2022 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the “Company”) is pleased to announce today that it has submitted the Company’s New Drug...